Evidence map›Paper›PMID 42609520›Full record

ArticleMedComm2026

Clinical Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy for Triple-Negative Breast Cancer and Tumor Immune Microenvironment Analysis: A Prospective-Retrospective Cohort Study.

Yongsheng Wang, Pengfei Qiu, Yuechen Wang, Xingchen Meng, Jiaxin Zhang, Haiqiang Liu, Zhiqiang Shi, Zhaopeng Zhang, Xiao Sun, Chunjian Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yongsheng WangBreast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.ORCID https://orcid.org/0000-0001-6252-684X
Pengfei QiuBreast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Yuechen WangBreast Disease Center Weifang People's Hospital Shandong Second Medical University Weifang China.
Xingchen MengBreast Disease Center Weifang People's Hospital Shandong Second Medical University Weifang China.ORCID https://orcid.org/0009-0009-1657-2955
Jiaxin ZhangBreast Disease Center Weifang People's Hospital Shandong Second Medical University Weifang China.
Haiqiang LiuDepartment of Anaesthesiology Weifang People's Hospital Shandong Second Medical University Weifang China.
Zhiqiang ShiBreast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Zhaopeng ZhangBreast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Xiao SunBreast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Chunjian WangBreast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
Xiangjing MengToxicology Research Center Shandong Academy of Occupational Health and Occupational Medicine Shandong First Medical University & Shandong Academy of Medical Sciences Jinan China.
Chunhui ZhengBreast Disease Center Weifang People's Hospital Shandong Second Medical University Weifang China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of immune checkpoint inhibitors combined with neoadjuvant chemotherapy (NAC) on surgical outcomes and immune remodeling remains underexplored. To investigate the efficacy and tumor immune microenvironment (TIME) changes of camrelizumab plus NAC for triple-negative breast cancer (TNBC), we collected TNBC patients receiving neoadjuvant immunochemotherapy (NIC) or NAC from clinical trials and routine practice, and set a series of endpoints, including total pathological complete response (pCR), breast pCR and TIME characteristics. After propensity score matching, the NIC cohort showed significantly higher rates of total pCR, breast pCR, and axillary pCR, and a lower rate of axillary lymph node dissection than the NAC cohort (all

Indexed as

camrelizumabimmunotherapyneoadjuvant chemotherapytriple‐negative breast cancertumor immune microenvironment

Identifiers

PMID42609520
PMCPMC13478840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.